# Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma

> **NCT05532397** · NA · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 10 (estimated)

## Conditions studied

- Glioma, Astrocytic

## Interventions

- **DRUG:** QPOP category 1
- **DRUG:** QPOP category 2

## Key facts

- **NCT ID:** NCT05532397
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-17
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532397, "Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05532397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*